Eli Lilly Surpasses Novo Nordisk as GLP-1 Market Leader
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Source: Fool
- Market Share Shift: Eli Lilly has captured 60% of the U.S. GLP-1 market, while Novo Nordisk's share has fallen to 39%, indicating Lilly's strong growth momentum in the obesity drug sector, which may impact Novo's future sales performance.
- Significant Revenue Growth: Lilly's Mounjaro and Zepbound generated over $11 billion in revenue in the recent quarter, showcasing triple-digit growth rates that not only enhance the company's overall financial performance but also strengthen its position in a competitive market.
- Manufacturing Capacity Boost: By ramping up production capabilities, Lilly has ensured product availability, addressing shortages from previous years, which has allowed more patients to receive timely treatment and further propelled market share growth.
- Clinical Study Advantage: Lilly's head-to-head study comparing Zepbound to Wegovy demonstrated superior weight loss results for Zepbound, potentially leading doctors and patients to prefer Lilly's products, thereby solidifying its market leadership.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 883.960
Low
950.00
Averages
1192
High
1500
Current: 883.960
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stock Futures Decline as Investors Eye Big Tech Earnings
- Market Sentiment: Stock index futures opened lower on Monday as investors remain cautious ahead of the upcoming earnings reports from major tech companies, reflecting concerns about future economic conditions.
- Meta Acquisition Blocked: Meta Platforms (META) was flat before the opening bell after the National Development and Reform Commission of China blocked its planned $2 billion acquisition of AI startup Manus, highlighting the complexities of international mergers and acquisitions.
- Eli Lilly's Acquisition: Eli Lilly (LLY) edged up 0.1% after agreeing to acquire Ajax Therapeutics for up to $2.3 billion in cash, a move that will enhance its presence in blood cancer therapies and potentially drive future growth.
- Verizon's Earnings Report: Verizon Communications (VZ) rose 3.9% ahead of the open, reporting Q1 non-GAAP EPS of $1.28, beating estimates by $0.07, although its revenue of $34.4 billion missed expectations, indicating strong competitive positioning despite challenges.
See More
Chaos Erupts at White House Correspondents' Dinner Amid Security Incident
- White House Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting evacuation of President Trump and officials, which has drawn widespread condemnation and highlights increasing political violence in the U.S.
- Investigation Closure: The Justice Department has ended its criminal investigation into Fed Chair Jerome Powell, clearing the way for Trump's nominee Kevin Warsh, which could significantly influence future monetary policy decisions.
- Iran Negotiation Halt: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks, resulting in Brent crude prices surpassing $106 per barrel, exerting downward pressure on stock futures amid faltering peace talks.
- Tesla AI Testing: Tesla is beta testing xAI's Grok chatbot for in-vehicle voice commands, aiming to enhance driver experience, but safety experts warn that such features could distract drivers and compromise road safety.
See More
Trump's White House Dinner Chaos Incident
- White House Dinner Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting the evacuation of Trump and other officials; Trump reported that one officer was shot but saved, highlighting the increasing political violence in the U.S.
- Iran Negotiation Cancellation: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks with Iran, stating that Iran could initiate dialogue by calling, which led Brent crude prices to surpass $106 per barrel, exerting downward pressure on stock futures.
- Fed Investigation Closure: The Justice Department ended its criminal investigation into Fed Chair Powell, clearing the way for Trump's nominee Warsh to gain support for confirmation, while Powell now faces a decision on whether to remain as a Fed governor after his term ends.
- Musk vs. Altman Trial: The trial between Musk and OpenAI CEO Altman begins today in Oakland, California, with Musk alleging in a $134 billion lawsuit that OpenAI failed to uphold its promise, which could significantly impact the future business trajectories of both tech leaders.
See More
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
- Acquisition Details: Eli Lilly announced a deal to acquire Ajax Therapeutics and its lead asset AJ1-11095, a once-daily oral JAK2 inhibitor for myelofibrosis, for up to $2.3 billion, including upfront and milestone-based payments.
- Strategic Investment Background: As a founding strategic investor in Ajax, Lilly has long believed in its approach and is excited about AJ1-11095's potential to deliver superior efficacy and tolerability, allowing patients to remain on therapy longer.
- Market Reaction: Eli Lilly's stock traded at $884.65, up 0.05% in pre-market hours on the NYSE, indicating a positive market response to the acquisition, reflecting investor optimism about the new drug's potential.
- Future Outlook: This acquisition not only strengthens Lilly's oncology portfolio but also has the potential to enhance its market share in treating myelofibrosis patients through the clinical success of AJ1-11095, further solidifying its industry leadership.
See More
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion
- Acquisition Amount: Eli Lilly announced it will acquire privately-held Ajax Therapeutics for up to $2.3 billion in cash, demonstrating its intent to expand in the blood cancer treatment sector while potentially enhancing its product portfolio diversity.
- Market Impact: This acquisition is expected to strengthen Eli Lilly's competitiveness in the blood cancer treatment market, particularly in new drug development and marketing, further solidifying its leadership position in the biopharmaceutical industry.
- Strategic Significance: By integrating Ajax's technology and R&D capabilities, Eli Lilly can accelerate the market entry of innovative drugs, thereby meeting the growing patient demand and enhancing the company's long-term profitability.
- Investor Confidence: The announcement of this transaction may bolster investor confidence in Eli Lilly's future growth potential, especially regarding market share expansion and new product development in the blood cancer treatment sector.
See More
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3B
- Acquisition Value: Eli Lilly has agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, which includes an upfront payment and additional payments contingent on achieving specific clinical and regulatory milestones, significantly enhancing Lilly's market position in blood cancers.
- Clinical Development Potential: Ajax is developing next-generation therapies for blood cancers, particularly the AJ1-11095, a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept data expected in 2026, potentially transforming the treatment landscape.
- Efficacy Expectations: AJ1-11095 is anticipated to provide deeper and more durable disease control compared to existing therapies for myelofibrosis and polycythemia vera, offering patients longer treatment options and improving their quality of life.
- Strategic Investment Confidence: As a founding strategic investor in Ajax, Lilly expresses strong confidence in the development of AJ1-11095, believing its efficacy and tolerability advantages will allow for broad applications in both first- and second-line settings, further solidifying Lilly's leadership in oncology.
See More
U.S. Stock Futures Decline as Investors Eye Big Tech Earnings
- Market Sentiment: Stock index futures opened lower on Monday as investors remain cautious ahead of the upcoming earnings reports from major tech companies, reflecting concerns about future economic conditions.
- Meta Acquisition Blocked: Meta Platforms (META) was flat before the opening bell after the National Development and Reform Commission of China blocked its planned $2 billion acquisition of AI startup Manus, highlighting the complexities of international mergers and acquisitions.
- Eli Lilly's Acquisition: Eli Lilly (LLY) edged up 0.1% after agreeing to acquire Ajax Therapeutics for up to $2.3 billion in cash, a move that will enhance its presence in blood cancer therapies and potentially drive future growth.
- Verizon's Earnings Report: Verizon Communications (VZ) rose 3.9% ahead of the open, reporting Q1 non-GAAP EPS of $1.28, beating estimates by $0.07, although its revenue of $34.4 billion missed expectations, indicating strong competitive positioning despite challenges.
See More
Chaos Erupts at White House Correspondents' Dinner Amid Security Incident
- White House Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting evacuation of President Trump and officials, which has drawn widespread condemnation and highlights increasing political violence in the U.S.
- Investigation Closure: The Justice Department has ended its criminal investigation into Fed Chair Jerome Powell, clearing the way for Trump's nominee Kevin Warsh, which could significantly influence future monetary policy decisions.
- Iran Negotiation Halt: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks, resulting in Brent crude prices surpassing $106 per barrel, exerting downward pressure on stock futures amid faltering peace talks.
- Tesla AI Testing: Tesla is beta testing xAI's Grok chatbot for in-vehicle voice commands, aiming to enhance driver experience, but safety experts warn that such features could distract drivers and compromise road safety.
See More
Trump's White House Dinner Chaos Incident
- White House Dinner Chaos: An armed man charged a security checkpoint during the White House Correspondents' Dinner, prompting the evacuation of Trump and other officials; Trump reported that one officer was shot but saved, highlighting the increasing political violence in the U.S.
- Iran Negotiation Cancellation: Trump canceled plans to send U.S. representatives to Pakistan for ceasefire talks with Iran, stating that Iran could initiate dialogue by calling, which led Brent crude prices to surpass $106 per barrel, exerting downward pressure on stock futures.
- Fed Investigation Closure: The Justice Department ended its criminal investigation into Fed Chair Powell, clearing the way for Trump's nominee Warsh to gain support for confirmation, while Powell now faces a decision on whether to remain as a Fed governor after his term ends.
- Musk vs. Altman Trial: The trial between Musk and OpenAI CEO Altman begins today in Oakland, California, with Musk alleging in a $134 billion lawsuit that OpenAI failed to uphold its promise, which could significantly impact the future business trajectories of both tech leaders.
See More
Eli Lilly Acquires Ajax Therapeutics for $2.3 Billion
- Acquisition Details: Eli Lilly announced a deal to acquire Ajax Therapeutics and its lead asset AJ1-11095, a once-daily oral JAK2 inhibitor for myelofibrosis, for up to $2.3 billion, including upfront and milestone-based payments.
- Strategic Investment Background: As a founding strategic investor in Ajax, Lilly has long believed in its approach and is excited about AJ1-11095's potential to deliver superior efficacy and tolerability, allowing patients to remain on therapy longer.
- Market Reaction: Eli Lilly's stock traded at $884.65, up 0.05% in pre-market hours on the NYSE, indicating a positive market response to the acquisition, reflecting investor optimism about the new drug's potential.
- Future Outlook: This acquisition not only strengthens Lilly's oncology portfolio but also has the potential to enhance its market share in treating myelofibrosis patients through the clinical success of AJ1-11095, further solidifying its industry leadership.
See More
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion
- Acquisition Amount: Eli Lilly announced it will acquire privately-held Ajax Therapeutics for up to $2.3 billion in cash, demonstrating its intent to expand in the blood cancer treatment sector while potentially enhancing its product portfolio diversity.
- Market Impact: This acquisition is expected to strengthen Eli Lilly's competitiveness in the blood cancer treatment market, particularly in new drug development and marketing, further solidifying its leadership position in the biopharmaceutical industry.
- Strategic Significance: By integrating Ajax's technology and R&D capabilities, Eli Lilly can accelerate the market entry of innovative drugs, thereby meeting the growing patient demand and enhancing the company's long-term profitability.
- Investor Confidence: The announcement of this transaction may bolster investor confidence in Eli Lilly's future growth potential, especially regarding market share expansion and new product development in the blood cancer treatment sector.
See More
Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3B
- Acquisition Value: Eli Lilly has agreed to acquire Ajax Therapeutics for up to $2.3 billion in cash, which includes an upfront payment and additional payments contingent on achieving specific clinical and regulatory milestones, significantly enhancing Lilly's market position in blood cancers.
- Clinical Development Potential: Ajax is developing next-generation therapies for blood cancers, particularly the AJ1-11095, a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development, with first proof-of-concept data expected in 2026, potentially transforming the treatment landscape.
- Efficacy Expectations: AJ1-11095 is anticipated to provide deeper and more durable disease control compared to existing therapies for myelofibrosis and polycythemia vera, offering patients longer treatment options and improving their quality of life.
- Strategic Investment Confidence: As a founding strategic investor in Ajax, Lilly expresses strong confidence in the development of AJ1-11095, believing its efficacy and tolerability advantages will allow for broad applications in both first- and second-line settings, further solidifying Lilly's leadership in oncology.
See More
